Timeline Entry
In 1921 Frederick Banting and Charles Best, working in J.J.R. Macleod's laboratory at the University of Toronto, produced pancreatic extracts that lowered blood sugar in diabetic dogs. With James Collip's later work on purification, that laboratory result quickly became a treatment that changed the prospects of people with diabetes.
Insulin therapy mattered because it turned severe diabetes from a condition commonly managed only through starvation diets and impending death into one that could be medically controlled, while also establishing a new model of therapeutic research linking laboratory science, hospital care, and industrial production.
Historical Significance
Before insulin, physicians could diagnose diabetes more confidently than they could treat it. By the early twentieth century, strict low-calorie regimens could sometimes prolong life, especially in children, but often at the cost of profound weakness and only temporary reprieve.
Insulin did not cure diabetes, but it made sustained treatment possible. Patients who would previously have died within months or a few years could now live far longer, provided they had regular access to the drug, careful monitoring, and dietary discipline.
The therapy depended on animal pancreases, chemical purification, standardized potency, hospital supervision, and commercial manufacture. Therapeutic success therefore rested on institutions and supply chains, not on a physician's bedside skill alone.
Insulin quickly became part of a contested scientific story. Banting, Best, Macleod, and Collip all played different roles, and historians also note the earlier work of researchers such as Nicolas Paulescu. The debate itself shows how modern discoveries are often collective, competitive, and shaped by questions of recognition.
Timeline Context
Diabetes had long been recognized, but nineteenth-century physiology made the pancreas central to understanding the disease. By the 1910s, clinicians could identify diabetes with increasing precision, yet treatment remained grim. Frederick Allen's severe dietary regimens could delay death in some cases, but they underscored how little medicine could actually reverse the metabolic crisis.
The breakthrough associated with 1921 was therefore a laboratory turning point, not the end of the story. Banting and Best demonstrated that pancreatic extracts could control diabetic symptoms in dogs; Collip helped purify the extract enough for human use; and in January 1922 Leonard Thompson became the first patient treated successfully after early attempts were refined. By 1923, insulin was already being standardized, publicly celebrated, and drawn into a wider therapeutic economy that would later characterize other twentieth-century drugs, including penicillin.
Legacy
Insulin entered medicine with extraordinary symbolic force. Newspapers and physicians described it as a rescue from a formerly hopeless disease, and for many patients it was exactly that. Yet its benefits were never automatic. Insulin therapy required money, regular supply, trained supervision, and the daily labour of patients and families. The history of insulin is therefore also a history of access, regimen, measurement, and dependence on durable medical infrastructure.
That longer legacy matters because insulin helped define what twentieth-century medicine increasingly promised: not merely diagnosis, but ongoing biochemical control of chronic disease. It showed both the power of modern therapeutics and the inequalities built into their distribution.
Further Reading
The standard historical account of the Toronto work, the personalities involved, and the making of insulin's public reputation.
Useful for placing insulin within the much longer history of diabetes, diagnosis, and treatment.
Helpful for understanding purification, laboratory organization, and the Canadian research culture around insulin.